ARIAD Pharmaceuticals

ARIAD Pharmaceuticals, Inc. is a global oncology company focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.

ARIAD Pharmaceuticals was acquired by Takeda Pharmaceutical on January 9, 2017

Type
Subsidiary
Parent Company
Takeda Pharmaceutical
HQ
Cambridge, US
Founded
1991
Website
ariad.com
ARIAD Pharmaceuticals was founded in 1991 and is headquartered in Cambridge, US

ARIAD Pharmaceuticals Office Locations

ARIAD Pharmaceuticals has offices in Cambridge, Minneapolis, Boston, San Antonio and in 9 other locations
Cambridge, US (HQ)
26 Landsdowne St
Show all (13)

ARIAD Pharmaceuticals Data and Metrics

ARIAD Pharmaceuticals Summary

Founding Date

1991
ARIAD Pharmaceuticals is a subsidiary of Takeda Pharmaceutical

ARIAD Pharmaceuticals Financial Metrics

ARIAD Pharmaceuticals's revenue was reported to be $118.8 m in FY, 2015 which is a 13% increase from the previous period.
USDFY, 2013FY, 2014FY, 2015

Revenue

45.6 m105.4 m118.8 m

Revenue growth, %

131%13%

Gross profit

35.9 m100.2 m116.7 m

Gross profit Margin, %

79%95%98%

Operating expense total

319.1 m265.6 m336.1 m

EBIT

(273.6 m)(160.2 m)(217.3 m)

EBIT margin, %

(600%)(152%)(183%)

Interest expense

153 k8.1 m18.1 m

Interest income

130 k85 k82 k

Pre tax profit

(273.7 m)(162 m)(234.6 m)

Income tax expense

439 k630 k3.4 m

Net Income

(274.2 m)(162.6 m)(231.2 m)
USDFY, 2013FY, 2014FY, 2015

Cash

237.2 m352.7 m230.9 m

Accounts Receivable

1.3 m8.4 m15.7 m

Inventories

419 k

Current Assets

244.9 m385.6 m275.2 m

PP&E

108.8 m203 m254.1 m

Total Assets

370.9 m603.9 m546.7 m

Accounts Payable

11.4 m10.8 m17 m

Total Debt

161.1 m443.1 m

Current Liabilities

72.2 m90 m132.3 m

Additional Paid-in Capital

1.2 b1.3 b1.3 b

Retained Earnings

(1.1 b)(1.2 b)(1.4 b)

Total Equity

185.5 m80.8 m(103.1 m)

Debt to Equity Ratio

2 x-4.3 x

Debt to Assets Ratio

0.3 x0.8 x

Financial Leverage

2 x7.5 x-5.3 x
USDFY, 2013FY, 2014FY, 2015

Net Income

(274.2 m)(162.6 m)(231.2 m)

Accounts Receivable

(1.3 m)(7.1 m)(7.3 m)

Inventories

(413 k)(560 k)1.1 m

Accounts Payable

2.5 m(137 k)5.5 m

Cash From Operating Activities

(221.9 m)(57.8 m)(159.2 m)

Cash From Investing Activities

26.1 m2 m(17.2 m)

Long-term Borrowings

(1.4 m)

Cash From Financing Activities

313.6 m171.1 m54.3 m

Interest Paid

153 k8.1 m7.3 m

Income Taxes Paid

17 k185 k238 k

ARIAD Pharmaceuticals Median Salaries

Source: 16 public H-1B filings from ARIAD Pharmaceuticals

ARIAD Pharmaceuticals Online and Social Media Presence

ARIAD Pharmaceuticals News and Updates

ARIAD Pharmaceuticals Company Life and Culture

You may also be interested in